Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment.
Shinobi Therapeutics has raised $68.0M in total funding. The most recent round was Series A. The last funding was announced in August 2024.
Shinobi Therapeutics's investors include Mitsubishi UFJ Capital, EQT Life Sciences, JIC Venture Growth Investments, F-Prime Capital, Yosemite.
Shinobi Therapeutics is headquartered in South San Francisco, United States.
Shinobi Therapeutics develops immune-evasive iPS cell therapies for cancer treatment.
Shinobi Therapeutics is at the Series A stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Shinobi Therapeutics — Funding & Investors." VCBacked, August 6, 2024, https://www.vcbacked.co/company/shinobi-therapeutics. Accessed July 19, 2026.
VCBacked. (2024). Shinobi Therapeutics — Funding & Investors. Retrieved July 19, 2026, from https://www.vcbacked.co/company/shinobi-therapeutics
{{cite web |title=Shinobi Therapeutics — Funding & Investors |url=https://www.vcbacked.co/company/shinobi-therapeutics |website=VCBacked |access-date=July 19, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated